Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 20/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924603 | 0.92 | GABRA5 (0.84) | GABRA5GABRA1 | |
| SCHEMBL2924213 | 0.90 | GABRA5 (1.00) | GABRA5 | |
| SCHEMBL109273 | 0.89 | GABRA5 (1.00) | GABRA5 | |
| SCHEMBL2922234 | 0.89 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2924240 | 0.89 | GABRA5 (0.80) | GABRA5GABRA1 | |
| SCHEMBL20241274 | 0.88 | GABRA5 (0.79) | GABRA5GABRA1 | |
| SCHEMBL28407452 | 0.88 | GABRA5 (0.82) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL29421368 | 0.88 | GABRA5 (0.79) | GABRA5GABRA1 | |
| SCHEMBL30592886 | 0.88 | GABRA5 (0.79) | GABRA5GABRA1 | |
| SCHEMBL2922227 | 0.88 | GABRA5 (1.00) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768821-B1 | SOLID FORMS OF (1,1-DIOXO-4-THIOMORPHOLINYL)-[6-[[3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLYL]METHOXY]-3-PYRIDINYL]-METHANONE | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-8975397-B2 | Solid forms | HOFFMANN-LA ROCHE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-20140329806-A1 | NOVEL SOLID FORMS | HOFFMANN-LA ROCHE INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2792360-A1 | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV | IP Gesellschaft für Management mbH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8846719-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130274468-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-8518974-B2 | Isoxazolo-pyridine derivatives | Hoffmann-La Roche Inc (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130172329-A1 | NOVEL SOLID FORMS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013057124-A1 | SOLID FORMS OF 1,L-DIOXO-4-THIOMORPHOLINYL)-[6-[[3(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLYL]METHOXY]-3-PYRIDINYL]-METHANONE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-07-19 | — | — | US | disclosed |
| EP-2227467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20130172329-A1 | NOVEL SOLID FORMS | F12, SLC10A1, CYP2F1 | GABRA5 3197/4885GABRA1 3294/4885GABRG2 3630/4885 |
| US-20130274468-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20140329806-A1 | NOVEL SOLID FORMS | F12, SLC10A1, CYP2F1 | GABRA5 3197/4885GABRA1 3294/4885GABRG2 3630/4885 |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.